ClinicalTrials.gg
Not yet recruitingNCT06964230Updated May 9, 2025

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

A Phase 2/3 interventional study of T3D-959 and Placebo Comparator in Alzheimer's Disease, sponsored by T3D Therapeutics, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-05-09.

Sponsored by T3D Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
376
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
252nd of 1,611
376 · median 73
Started
2026
with 92 others
Phase 2/3
42 of 1,942
5 open now
Primary completion
2031-04
later than 423 of 446 live
Registered
1,804th of 1,942
by date

Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 252nd largest by planned enrollment of the 1,611 interventional ones that give a count, is one of 93 that started in 2026, is one of 42 in phase 2/3, reaches primary completion later than 423 of the 446 other live ones, and was the 1,804th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

343 more — sign in →

All 348 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,942 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's. The aims of the trial are to affirm potential therapeutic efficacy and safety observed in earlier clinical trials and assess the potential to modify the course of disease. The drug will be compared to placebo and administered orally to patients once a day for 78 weeks.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled study of T3D-959 30mg in subjects with clinical mild-to-moderate Alzheimer's Disease and a biological diagnosis of AD pathology, as defined by a validated plasma biomarker (presently %p-tau217 plasma biomarker). This study is designed as a seamless group sequential design where estimates of treatment effect on cognitive and functional scales will be evaluated in an interim analysis by independent statisticians. The sample size will be re-estimated to ensure the study is sufficiently powered to demonstrate efficacy of T3D-959 in cognition and function.

Subjects will be assigned to one of two treatment arms (1:1 ratio) in a randomized, double-blind fashion, stratified by sex and ApoE4 genotype. Study medication will be taken once daily for 78 weeks. Safety/tolerability, efficacy and exploratory assessments will be evaluated for changes from baseline to end of treatment (78 weeks). Subjects will be followed for four weeks after the end of treatment.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • T3D-959
  • Mild-to-Moderate Alzheimer's Disease Severity
  • New Drug Treatment Being Tested
  • Once-a-day oral drug administration
  • Phase 2b/3 Study T3D959-301
  • Brain Metabolism
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject aged 50-90 years old inclusive at the time of
  2. Subject (or legal representative) and caregiver must sign an Informed Consent to participate in the study.
  3. Subject has a caregiver, an identified adult who, in the opinion of the investigator, has sufficient contact to knowledgeably report on the subject's cognition, function, behavior, safety, compliance and adherence. Same caregiver should, whenever possible, assist the subject throughout the duration of the trial
  4. Subject has a biological diagnosis of AD pathology, as assessed by a validated plasma biomarker (presently %p-tau217 plasma biomarker), according to the NIA-AA (National Institute of Aging - Alzheimer's Association) criteria at screening
  5. Subject has a clinical diagnosis of mild to moderate AD (Stage 4 or 5) according to the NIA-AA (National Institute of Aging - Alzheimer's Association) criteria at screening
  6. Meets criteria for mild-to-moderate cognitive impairment with (MMSE) score of 14 through 26 at the screening visit.
  7. Modified Hachinski \< 4 at screening
  8. Clinical Dementia Rating is 0.5 to 2.0 at screening
  9. Visual and auditory acuity adequate for neuropsychological testing
  10. Medical stability for this study as confirmed by review of records, comprehensive physical exam, neurological exam, and laboratory tests
  11. Washout and stability of all concurrent medication according to the exclusion criteria listed below
  12. Able to swallow oral medications

Exclusion criteria

Exclusion Criteria:

  1. Subject has a current diagnosis of a significant psychiatric illness per the V (DSM-V) including but not limited to major depressive disorder, anxiety disorders and is in an acute phase/episode; or the subject has a current diagnosis or history of schizophrenia or bipolar disorder; or has current signs of suicidality or history of suicide attempt
  2. Subject with untreated clinical depression at screening; Geriatric Depression Scale (GDS) Short Form > 9
  3. Evidence of lesion(s) on brain MRI at Screening that could indicate a dementia diagnosis other than Alzheimer's disease
  4. Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter [mm] or less at the greatest diameter); a single macrohemorrhage >10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and \<1 centimeter [cm] at their greatest diameter need not be exclusionary)
  5. Subject has a current diagnosis of a neurological disease other than AD, which has or could result in cognitive impairment, including, but not limited to, any of the following:

    1. History of clinically significant stroke or multiple strokes as ascertained by history and/or brain imaging findings, or history of 's within 12 months prior to baseline
    2. History of serious brain infection
    3. History of or current space occupying cerebral lesion
    4. History of clinically significant concussion or repeated head trauma associated with sustained cognitive impairment in the last 5 years
    5. Huntington's Disease
    6. Parkinson's Disease
    7. Dementia predominantly of a non-Alzheimer's type (vascular dementia, frontotemporal dementia, Parkinson's dementia, substance-induced dementia)
    8. Normal pressure hydrocephalus
    9. History of seizures (except for childhood febrile) or epilepsy
  6. With glycosylated () ≥ 10 at screening
  7. Subject with a diagnosis of unstable diabetes
  8. Subject with clinically significant thyroid disease at screening TSH >5 and abnormal T3/T4
  9. Subject has any evidence of hepatic impairment or renal insufficiency, including any of the following values at the screening visit:

    1. Serum (ALT) and/or aspartate aminotransferase (AST) value that is twice the
    2. A serum total value that exceeds 2 mg/dL
    3. Serum creatinine level >1.5 mg/dL in men or > 1.4 mg/dL in women
    4. Positive urinalysis consistent with renal impairment
    5. Estimated (eGFR) \< 50 mL/min/1.73m2
    6. Gamma glutamyl-transpeptidase (GGT) twice the upper limit of normal
  10. Subject is positive for surface antigen (HBsAg) or anti- virus (HCV) antibodies at the screening visit
  11. Subject has a history of moderate or severe congestive heart failure, class III or IV, within 12 months prior to baseline
  12. Subject has experienced a previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 6 months prior to the baseline (visit 2)
  13. Subject has blood pressure reading at screening that is greater than 160/100 mmHg. Subjects with elevated BP will be allowed at the discretion of the principal investigator. Blood pressure will be measured after the subject has been supine for at least 5 minutes followed by repeat measurement after standing for at least 3 minutes. Subjects will be excluded if a significant diastolic (15 mmHg) drop in blood pressure or symptomatic presyncope occurred
  14. Subject has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal, endocrine, rheumatological, immunological, infection, skin and subcutaneous tissue disorder or metabolic disturbance
  15. Subject has a history of infection
  16. Subject has a history of marijuana abuse or dependence (except topical CBD) within 1 year of the screening visit
  17. Subject has a history of alcohol, drug abuse or dependence (except nicotine dependence) within 2 years of the screening visit
  18. Subject has a history of cancer within 5 years of the screening visit (other than non-melanoma skin cancer, stable non-progressive prostate cancer not requiring treatment or in situ cervical cancer)
  19. Subject has any surgical or medical condition which may significantly alter the absorption of any drug substance including, but not limited to, any of the following:

    1. History of major gastrointestinal tract surgery (e.g. bariatric surgery)
    2. Currently active inflammatory bowel syndrome
  20. Female subject who is pregnant, nursing or of and not practicing effective
  21. Subject is required to take excluded medications as specified in the Excluded Medications section below.
  22. Subject has a known or suspected intolerance or to the study drug, closely related compounds, or any of their stated ingredients
  23. Subject resides in hospital or moderate to high dependency continuous care facility
  24. Evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
376 participants (estimated)

Study arms

  • Placebo comparator
    Placebo, matching T3D-959 active capsules

    Placebo Comparator: Placebo, matching T3D-959 active capsules, is pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects randomized to placebo will ingest two size 0 placebo capsules once per day in the morning.

    Other: Placebo Comparator

  • Experimental
    30mg T3D-959

    Experimental: 30mg T3D-959 Arm Description: Experimental: T3D-959 30 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength contains 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest two size 0, 15mg capsules once per day in the morning.

    Drug: T3D-959

Interventions

  • Experimental: T3D-959 30 mg dose: T3D-959 is a small molecule dual nuclear receptor agonist that regulates transcription of genes, in particular those involved in glucose energy and lipid metabolism. T3D-959 is 15-times more potent for PPAR delta than for the secondary target of the drug, PPAR gamma. The 15 mg strength capsules contain 15mg T3D-959, pregelatinized starch NF, magnesium stearate NF, and size 0, hard gelatin, white/white, opaque, unmarked capsules. Subjects will ingest two size 0, 15mg capsules once per day in the morning.

  • OtherPlacebo Comparator

    Placebo used to compare to T3D-959 drug

06

What researchers measure

Primary outcomes

  1. Change from baseline to end of treatment in ADAS-Cog13 and ADCS-iADL

    Primary Efficacy Endpoint • Co-primary endpoints of Alzheimer's Disease Assessment Scale cognitive subscale, 13-items (ADAS-Cog13) with a score range of 0-85 (higher scores indicating greater dysfunction) and Alzheimer's Disease Cooperative Study Instrumental Activities of Daily Living (ADCS-iADL) with a score range of 0-56 (lower scores indicating worse performance), in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology. ADAS-cog 13

    Time frame: 78 weeks

Secondary outcomes

  1. Change from Baseline to End of Treatment in plasma AB42/40 ratio, in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology

    Time frame: 78 weeks

  2. Change from Baseline to End of Treatment in disease stage progression on the Clinical Dementia Rating Scale-Global (CDR-Global), in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology

    CDR global score has a range of 0-3 with a higher score indicating greater dementia severity

    Time frame: 78 weeks

  3. Change from baseline to end of treatment in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB), in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology

    CDR-SB has a score range of 0-18 with a higher number indicating greater dementia severity

    Time frame: 78 weeks

  4. Change from Baseline to End of Treatment on the integrated Alzheimer's Disease Rating Scale (iADRS), in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology

    The iADRS is a composite scale that is calculated as a linear combination of total scores of the two individual components, the ADAS-Cog13 (score range 0-85) and the instrumental items of the ADCS-ADL (ADCS-iADL; score range 0-56)1 • The iADRS score ranges from 0-141 with lower scores indicating worse performance.

    Time frame: 78 weeks

Other outcomes

  1. Additional Endpoints (Exploratory) • Change from Baseline to End of Treatment in plasma proteomic biomarker levels (i.e. Neurogranin, GFAP, MTBR-243)

    Time frame: 78 weeks

07

Study locations

1 site
  • T3D Therapeutics, Inc.
    Durham, North Carolina 27713, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2031, 54 months later.

Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 59. This study's planned 54 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
May 9, 2025
StartEst.
Oct 26, 2026
Primary completionEst.
Apr 2031
CompletionEst.
Jun 2031
Last update
May 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06964230
Lead sponsor
T3D Therapeutics, Inc.
Responsible party
John Didsbury (Chief Executive Officer, T3D Therapeutics, Inc.) — Principal investigator
First posted
May 9, 2025
Start date
Oct 26, 2026 (estimated)
Primary completion
Apr 2031 (estimated)
Completion
Jun 2031 (estimated)
Last update
May 9, 2025

Study contacts

Blake E Swearingen, MS
Contact
blakeswearingen@t3dtherapeutics.com
919-622-3409
John Didsbury, Ph.D., Chief Executive Officer
Contact
johndidsbury@t3dtherapeutics.com
919-237-4897
John Didsbury, Chief Executive Officer, Ph.D
study director · T3D Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: T3D-959

Start the discussion